Cargando…
Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport
HIV-1 transactivator of transcription (Tat) has a great impact on the development of HIV-1 associated neurocognitive disorders through disrupting dopamine transmission. This study determined the mutational effects of human dopamine transporter (hDAT) on basal and Tat-induced inhibition of dopamine t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329121/ https://www.ncbi.nlm.nih.gov/pubmed/33537927 http://dx.doi.org/10.1007/s11481-021-09984-5 |
_version_ | 1783732434060181504 |
---|---|
author | Quizon, Pamela M. Yuan, Yaxia Zhu, Yike Zhou, Yi Strauss, Matthew J. Sun, Wei-Lun Zhan, Chang-Guo Zhu, Jun |
author_facet | Quizon, Pamela M. Yuan, Yaxia Zhu, Yike Zhou, Yi Strauss, Matthew J. Sun, Wei-Lun Zhan, Chang-Guo Zhu, Jun |
author_sort | Quizon, Pamela M. |
collection | PubMed |
description | HIV-1 transactivator of transcription (Tat) has a great impact on the development of HIV-1 associated neurocognitive disorders through disrupting dopamine transmission. This study determined the mutational effects of human dopamine transporter (hDAT) on basal and Tat-induced inhibition of dopamine transport. Compared to wild-type hDAT, the maximal velocity (V(max)) of [(3)H]dopamine uptake was decreased in D381L and Y88F/D206L/H547A, increased in D206L/H547A, and unaltered in D206L. Recombinant TatR(1 − 86) inhibited dopamine uptake in wild-type hDAT, which was attenuated in either DAT mutants (D206L, D206L/H547A, and Y88F/D206L/H547A) or mutated TatR(1 − 86) (K19A and C22G), demonstrating perturbed Tat-DAT interaction. Mutational effects of hDAT on the transporter conformation were evidenced by attenuation of zinc-induced increased [(3)H]WIN35,428 binding in D206L/H547A and Y88F/D206A/H547A and enhanced basal MPP(+) efflux in D206L/H547A. H547A-induced outward-open transport conformational state was further validated by enhanced accessibility to MTSET ([2-(trimethylammonium)ethyl]-methanethiosulfonate) of an inserted cysteine (I159C) on a hDAT background.. Furthermore, H547A displayed an increase in palmitoylation inhibitor-induced inhibition of dopamine uptake relative to wide-type hDAT, indicating a change in basal palmitoylation in H547A. These results demonstrate that Y88F, D206L, and H547A attenuate Tat inhibition while preserving DA uptake, providing insights into identifying targets for improving DAT-mediated dopaminergic dysregulation. GRAPHICAL ABSTRACT: HIV-1 Tat inhibits dopamine uptake through human dopamine transporter (hDAT) on the presynaptic terminal through a direct allosteric interaction. Key hDAT residues D-H547, D-Y88, and D-D206 are predicted to be involved in the HIV-1 Tat-DAT binding. Mutating these residues attenuates this inhibitory effect by disrupting the Tat-hDAT interaction [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11481-021-09984-5. |
format | Online Article Text |
id | pubmed-8329121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-83291212021-12-29 Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport Quizon, Pamela M. Yuan, Yaxia Zhu, Yike Zhou, Yi Strauss, Matthew J. Sun, Wei-Lun Zhan, Chang-Guo Zhu, Jun J Neuroimmune Pharmacol Original Article HIV-1 transactivator of transcription (Tat) has a great impact on the development of HIV-1 associated neurocognitive disorders through disrupting dopamine transmission. This study determined the mutational effects of human dopamine transporter (hDAT) on basal and Tat-induced inhibition of dopamine transport. Compared to wild-type hDAT, the maximal velocity (V(max)) of [(3)H]dopamine uptake was decreased in D381L and Y88F/D206L/H547A, increased in D206L/H547A, and unaltered in D206L. Recombinant TatR(1 − 86) inhibited dopamine uptake in wild-type hDAT, which was attenuated in either DAT mutants (D206L, D206L/H547A, and Y88F/D206L/H547A) or mutated TatR(1 − 86) (K19A and C22G), demonstrating perturbed Tat-DAT interaction. Mutational effects of hDAT on the transporter conformation were evidenced by attenuation of zinc-induced increased [(3)H]WIN35,428 binding in D206L/H547A and Y88F/D206A/H547A and enhanced basal MPP(+) efflux in D206L/H547A. H547A-induced outward-open transport conformational state was further validated by enhanced accessibility to MTSET ([2-(trimethylammonium)ethyl]-methanethiosulfonate) of an inserted cysteine (I159C) on a hDAT background.. Furthermore, H547A displayed an increase in palmitoylation inhibitor-induced inhibition of dopamine uptake relative to wide-type hDAT, indicating a change in basal palmitoylation in H547A. These results demonstrate that Y88F, D206L, and H547A attenuate Tat inhibition while preserving DA uptake, providing insights into identifying targets for improving DAT-mediated dopaminergic dysregulation. GRAPHICAL ABSTRACT: HIV-1 Tat inhibits dopamine uptake through human dopamine transporter (hDAT) on the presynaptic terminal through a direct allosteric interaction. Key hDAT residues D-H547, D-Y88, and D-D206 are predicted to be involved in the HIV-1 Tat-DAT binding. Mutating these residues attenuates this inhibitory effect by disrupting the Tat-hDAT interaction [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11481-021-09984-5. Springer US 2021-02-03 2021 /pmc/articles/PMC8329121/ /pubmed/33537927 http://dx.doi.org/10.1007/s11481-021-09984-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Quizon, Pamela M. Yuan, Yaxia Zhu, Yike Zhou, Yi Strauss, Matthew J. Sun, Wei-Lun Zhan, Chang-Guo Zhu, Jun Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport |
title | Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport |
title_full | Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport |
title_fullStr | Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport |
title_full_unstemmed | Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport |
title_short | Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport |
title_sort | mutations of human dopaminetransporter at tyrosine88, aspartic acid206, and histidine547 influence basal and hiv-1 tat‐inhibited dopamine transport |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329121/ https://www.ncbi.nlm.nih.gov/pubmed/33537927 http://dx.doi.org/10.1007/s11481-021-09984-5 |
work_keys_str_mv | AT quizonpamelam mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport AT yuanyaxia mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport AT zhuyike mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport AT zhouyi mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport AT straussmatthewj mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport AT sunweilun mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport AT zhanchangguo mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport AT zhujun mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport |